R
Rezolute
Biotech & Life Sciences · Louisville, United States · Founded 2010 · IPO 2012
Specializing in the development of drug therapies for patients with metabolic and orphan diseases MoreLess
A late-stage biopharmaceutical company that specializes in developing therapies for rare diseases. The company's primary focus is on conditions with significant unmet medical needs, particularly congenital hyperinsulinism (HI), a rare pediatric genetic disorder characterized by excessive insulin secretion, leading to persistent hypoglycemia.
The company's lead product candidate, RZ358, is a human monoclonal antibody that is in late-stage clinical development for the treatment of congenital HI. RZ358 is designed to bind to and inhibit the activity of insulin, thereby reducing the frequency and severity of hypoglycemic events. Rezolute is also developing RZ402, an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME).
The company's business model is centered on the development and commercialization of its product candidates. Rezolute's target market includes pediatric and adult patients with rare diseases, as well as the physicians and healthcare providers who treat them. The company's revenue model will be based on the sale of its approved products.
Keywords: biopharmaceutical, rare diseases, congenital hyperinsulinism, hypoglycemia, monoclonal antibody, clinical development, orphan drugs, pediatric, genetic disorders, diabetic macular edema.
Company overview
Rezolute company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2010
- Headquarters
- Louisville, United States
- Employees
- 73
- Open positions
- 7
- Dealroom signal
- 74.8
Valuation & funding
Rezolute funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2025 | $90M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2024 | $6.7M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2024 | $60M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | May 2022 | $130M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Oct 2021 | $55M | — | Undisclosed | — |
| POST IPO DEBTDebt | Apr 2021 | SLR Capital Partners · Armentum Partners | — | ||
| POST IPO EQUITYOther financing | Oct 2020 | CAM Capital | — | ||
| POST IPO EQUITYOther financing | Jan 2019 | Genexine · HANDOK | ↗ | ||
| CONVERTIBLEOther financing | Apr 2018 | Undisclosed | ↗ | ||
| POST IPO EQUITYOther financing | Jun 2017 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$80M | — |
| 2025 | $0 | — | −$80M | — |
| 2024 | $0 | — | −$67M | — |
| 2023 | $0 | — | −$52M | — |
| 2022 | $0 | — | −$42M | — |
| 2021 | $0 | — | −$22M | — |
| 2020 | $0 | — | −$20M | — |
Growth signals
Rezolute website traffic
Latest recorded traffic for Rezolute is 4.4K monthly website visits, down 18.5% over the last three months. Rezolute's team declined 14.1% over the past year.
Hiring
Open positions at Rezolute
Current openings linked to this company in Dealroom.
Comparisons
Rezolute compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Rezolute's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Rezolute's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Rezolute has talent and traffic
team presence
In the news
Latest news about Rezolute
Recent press, funding announcements, and product moves mentioning Rezolute — open to read from the original sources.
Market sentiment
What the market is saying about Rezolute
An AI-synthesized read of the highest-engagement posts about Rezolute on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rezolute’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.